Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease
- PMID: 26895143
- PMCID: PMC4833539
- DOI: 10.1002/pbc.25944
Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease
Abstract
Background: The Patient Reported Outcomes Measurement Information System (PROMIS®) has developed pediatric self-report scales measuring several unidimensional health attributes (domains) suitable for use in clinical research, but these measures have not yet been validated in sickle cell disease (SCD).
Procedure: A convenience sample of SCD children, aged 8-17 years, from two sickle cell programs was recruited at routine clinic visits, including some for hydroxyurea monitoring or monthly transfusions. Children completed PROMIS pediatric items using an online data collection platform, the PROMIS Assessment Center Web site.
Results: A total of 235 participants (mean age 12.5 ± 2.8 years, 49.8% female) participated in the study. Adolescents (ages 12-17 years) reported significantly higher pain interference and depressive symptoms, and worse lower extremity physical functioning domain scores compared to younger children (ages 8-11 years). Female participants reported significantly higher pain interference, fatigue, and depressive symptoms, and worse lower extremity physical functioning domain scores compared with their male counterparts. Participants with hip or joint problems that limited usual activities reported significantly higher pain, fatigue, and depressive symptoms scores, and worse upper/lower extremity physical functioning scores as did participants who had experienced sickle pain in the previous 7 days.
Conclusions: PROMIS pediatric measures are feasible in a research setting and identify expected differences in known group comparisons in a sample of SCD children. The large domain score differences between those with or without SCD-related complications suggest the potential usefulness of these measures in clinical research, but further validation studies are needed, particularly in clinical practice settings.
Keywords: PROMIS; health-related quality of life; sickle cell disease.
© 2016 Wiley Periodicals, Inc.
Conflict of interest statement
DD was an unpaid member of the Board of Directors for the PROMIS Health Organization when this study was conducted. Dr. DeWalt was also an author of some of the items in the PROMIS instruments and owns the copyright for these items. Dr. DeWalt has given an unlimited free license for the use of the materials to the PROMIS Health Organization.
Comment in
-
Hydroxyurea and Pain History in Relation to Patient-Reported Outcomes Using PROMIS Measures and the Frequency of Assessments in Sickle Cell Disease Patients.Pediatr Blood Cancer. 2017 Jan;64(1):203. doi: 10.1002/pbc.26059. Epub 2016 May 17. Pediatr Blood Cancer. 2017. PMID: 27187560 No abstract available.
-
Reply to comment on: Hydroxyurea and pain history in relation to patient-reported outcomes using PROMIS® measures and the frequency of assessments in sickle cell disease patients.Pediatr Blood Cancer. 2017 Jan;64(1):204. doi: 10.1002/pbc.26095. Epub 2016 Sep 8. Pediatr Blood Cancer. 2017. PMID: 27605162 No abstract available.
Similar articles
-
Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease.Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):542-545. doi: 10.1182/asheducation-2017.1.542. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222303 Free PMC article. Review.
-
What is the future of patient-reported outcomes in sickle-cell disease?Expert Rev Hematol. 2020 Nov;13(11):1165-1173. doi: 10.1080/17474086.2020.1830370. Epub 2020 Oct 15. Expert Rev Hematol. 2020. PMID: 33034214 Free PMC article. Review.
-
Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery.Pediatr Blood Cancer. 2016 Jun;63(6):1038-45. doi: 10.1002/pbc.25931. Epub 2016 Feb 8. Pediatr Blood Cancer. 2016. PMID: 26853841 Free PMC article.
-
PROMIS(®) pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions.Qual Life Res. 2015 Sep;24(9):2195-208. doi: 10.1007/s11136-015-0953-3. Epub 2015 Feb 26. Qual Life Res. 2015. PMID: 25715946 Free PMC article.
-
Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease.Qual Life Res. 2018 Jan;27(1):249-257. doi: 10.1007/s11136-017-1697-z. Epub 2017 Sep 7. Qual Life Res. 2018. PMID: 28884421 Free PMC article.
Cited by
-
A preliminary investigation of the psychometric properties of PROMIS® scales in emerging adults with sickle cell disease.Health Psychol. 2019 May;38(5):386-390. doi: 10.1037/hea0000696. Health Psychol. 2019. PMID: 31045421 Free PMC article.
-
Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease.Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):542-545. doi: 10.1182/asheducation-2017.1.542. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222303 Free PMC article. Review.
-
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.Blood Adv. 2019 Dec 10;3(23):3982-4001. doi: 10.1182/bloodadvances.2019000882. Blood Adv. 2019. PMID: 31809538 Free PMC article.
-
What is the future of patient-reported outcomes in sickle-cell disease?Expert Rev Hematol. 2020 Nov;13(11):1165-1173. doi: 10.1080/17474086.2020.1830370. Epub 2020 Oct 15. Expert Rev Hematol. 2020. PMID: 33034214 Free PMC article. Review.
-
Pain-measurement tools in sickle cell disease: where are we now?Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):534-541. doi: 10.1182/asheducation-2017.1.534. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222302 Free PMC article. Review.
References
-
- Singh PC, Ballas SK. Emerging drugs for sickle cell anemia. Expert Opinion on Emerging Drugs. 2014;(0):1–15. - PubMed
-
- Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012;59(2):377–385. - PubMed
-
- Varni JW, Limbers CA. The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents. Pediatr Clin North Am. 2009;56(4):843–863. - PubMed
Publication types
MeSH terms
Grants and funding
- U01AR052170/AR/NIAMS NIH HHS/United States
- U54AR057943/AR/NIAMS NIH HHS/United States
- U01 AR052170/AR/NIAMS NIH HHS/United States
- U01AR052181/AR/NIAMS NIH HHS/United States
- U01AR057940/AR/NIAMS NIH HHS/United States
- U01AR057954/AR/NIAMS NIH HHS/United States
- U01 AR057929/AR/NIAMS NIH HHS/United States
- U01 AR052181/AR/NIAMS NIH HHS/United States
- U54AR057951/AR/NIAMS NIH HHS/United States
- U54AR057926/AR/NIAMS NIH HHS/United States
- U01 AR057954/AR/NIAMS NIH HHS/United States
- U01AR057948/AR/NIAMS NIH HHS/United States
- U01 AR057940/AR/NIAMS NIH HHS/United States
- U01 AR052177/AR/NIAMS NIH HHS/United States
- U01AR052186/AR/NIAMS NIH HHS/United States
- U01AR052171/AR/NIAMS NIH HHS/United States
- U01 AR057948/AR/NIAMS NIH HHS/United States
- U01 AR057956/AR/NIAMS NIH HHS/United States
- U01 AR052158/AR/NIAMS NIH HHS/United States
- U01 AR057971/AR/NIAMS NIH HHS/United States
- U01AR052158/AR/NIAMS NIH HHS/United States
- U01AR057936/AR/NIAMS NIH HHS/United States
- U01AR052155/AR/NIAMS NIH HHS/United States
- U01 AR057967/AR/NIAMS NIH HHS/United States
- U01AR057929/AR/NIAMS NIH HHS/United States
- U01 AR052155/AR/NIAMS NIH HHS/United States
- U01AR057956/AR/NIAMS NIH HHS/United States
- U01AR057967/AR/NIAMS NIH HHS/United States
- U01AR052177/AR/NIAMS NIH HHS/United States
- U54 AR057943/AR/NIAMS NIH HHS/United States
- U01 AR052171/AR/NIAMS NIH HHS/United States
- U01 AR057936/AR/NIAMS NIH HHS/United States
- U01 AR052186/AR/NIAMS NIH HHS/United States
- U54 AR057951/AR/NIAMS NIH HHS/United States
- U01AR057971/AR/NIAMS NIH HHS/United States
- U54 AR057926/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical